Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily TZP-102 for symptoms of diabetic gastroparesis
2011-002594-33Phase 2Completed
- Sponsor
- Tranzyme Pharma
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gastroparesis, diabetic gastroparesis, diabetes mellitus type 1 (T1D) and 1 more comparing TZP-102 once daily with Placebo once daily (2 arms). Primary endpoint: Change from baseline in GSDD symptom scores. Started Aug 2011; status: completed.
02
Drugs
TZP-102
03
Conditions
gastroparesisdiabetic gastroparesisdiabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-002594-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002594-33.